Trial Profile

A Phase II Trial of Combination of Camrelizumab and Neoadjuvant Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Paclitaxel (Primary) ; Gimeracil/oteracil/tegafur
Indications Oesophageal cancer; Squamous cell cancer; Thoracic neoplasms
Focus Therapeutic Use

13 Sep 2022 Results (n=47; From May 2020 to December 2021) assessing the safety and efficacy of three courses of camrelizumab plus chemotherapy for treating locally advanced esophageal squamous cell carcinoma, presented at the 47th European Society for Medical Oncology Congress.
08 Jun 2021 Results (n=25) assessing safety and feasibility of the neoadjuvant treatment programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
22 Jun 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com